
## Sushama Talegaonkar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/144143/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development and bioavailability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 227-243.	4.3	567
2	Zinc oxide nanoparticles: a promising nanomaterial for biomedical applications. Drug Discovery Today, 2017, 22, 1825-1834.	6.4	520
3	Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 68, 513-25.	4.3	410
4	Nanoemulsion Components Screening and Selection: a Technical Note. AAPS PharmSciTech, 2009, 10, 69-76.	3.3	368
5	Metal nanoparticles: a theranostic nanotool against cancer. Drug Discovery Today, 2015, 20, 1143-1151.	6.4	236
6	Ceramic Nanoparticles: Fabrication Methods and Applications in Drug Delivery. Current Pharmaceutical Design, 2015, 21, 6165-6188.	1.9	232
7	Microemulsions: A Novel Approach to Enhanced Drug Delivery. Recent Patents on Drug Delivery and Formulation, 2008, 2, 238-257.	2.1	212
8	Recent approaches for the treatment of periodontitis. Drug Discovery Today, 2008, 13, 932-943.	6.4	173
9	CNS Drug Delivery Systems: Novel Approaches. Recent Patents on Drug Delivery and Formulation, 2009, 3, 71-89.	2.1	165
10	Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discovery Today, 2009, 14, 1067-1074.	6.4	153
11	Cellulose nanofiber aerogel as a promising biomaterial for customized oral drug delivery. International Journal of Nanomedicine, 2017, Volume 12, 2021-2031.	6.7	135
12	Multiple Emulsions: An Overview. Current Drug Delivery, 2006, 3, 429-443.	1.6	129
13	Melanoma treatment: from conventional to nanotechnology. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2283-2302.	2.5	128
14	Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. European Journal of Pharmaceutical Sciences, 2009, 36, 580-590.	4.0	124
15	Niosomes in sustained and targeted drug delivery: some recent advances. Journal of Drug Targeting, 2009, 17, 671-689.	4.4	123
16	Role of CD44 in tumour progression and strategies for targeting. Journal of Drug Targeting, 2012, 20, 561-573.	4.4	114
17	The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opinion on Therapeutic Patents, 2011, 21, 561-576.	5.0	111
18	Microemulsions as a Surrogate Carrier for Dermal Drug Delivery. Drug Development and Industrial Pharmacy. 2009. 35. 525-547.	2.0	97

#	Article	IF	CITATIONS
19	Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats. European Journal of Pharmaceutical Sciences, 2011, 44, 241-249.	4.0	93
20	Nanocarrier based formulation of Thymoquinone improves oral delivery: Stability assessment, in vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces, 2013, 102, 822-832.	5.0	93
21	Topotecan–tamoxifen duple PLGA polymeric nanoparticles: Investigation of in vitro, in vivo and cellular uptake potential. International Journal of Pharmaceutics, 2014, 473, 384-394.	5.2	89
22	Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability. AAPS PharmSciTech, 2019, 20, 121.	3.3	89
23	Assessing the potential of lignin nanoparticles as drug carrier: Synthesis, cytotoxicity and genotoxicity studies. International Journal of Biological Macromolecules, 2020, 152, 786-802.	7.5	89
24	Design and Development of Oral Oil in Water Ramipril Nanoemulsion Formulation: In Vitro and In Vivo Assessment. Journal of Biomedical Nanotechnology, 2007, 3, 28-44.	1.1	87
25	Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. International Journal of Pharmaceutics, 2014, 461, 403-410.	5.2	87
26	Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. Colloids and Surfaces B: Biointerfaces, 2015, 128, 448-456.	5.0	86
27	Chemical penetration enhancers: a patent review. Expert Opinion on Therapeutic Patents, 2009, 19, 969-988.	5.0	85
28	Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation. International Journal of Pharmaceutics, 2012, 422, 436-444.	5.2	79
29	Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. Colloids and Surfaces B: Biointerfaces, 2014, 122, 423-431.	5.0	67
30	Nanocarrier for the Transdermal Delivery of an Antiparkinsonian Drug. AAPS PharmSciTech, 2009, 10, 1093-1103.	3.3	66
31	Enhanced Transdermal Drug Delivery Techniques: An Extensive Review of Patents. Recent Patents on Drug Delivery and Formulation, 2009, 3, 105-124.	2.1	66
32	Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 120-131.	4.3	65
33	Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. Colloids and Surfaces B: Biointerfaces, 2013, 111, 346-353.	5.0	65
34	Microscopic and spectroscopic evaluation of novel PLGA–chitosan Nanoplexes as an ocular delivery system. Colloids and Surfaces B: Biointerfaces, 2011, 82, 397-403.	5.0	63
35	Development of a novel synergistic thermosensitive gel for vaginal candidiasis: An in vitro, in vivo evaluation. Colloids and Surfaces B: Biointerfaces, 2013, 103, 275-282.	5.0	61
36	Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein. Life Sciences, 2008, 83, 250-259.	4.3	60

#	Article	IF	CITATIONS
37	Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its <i>in vitro</i> Behavior and tumor amelioration potential. Drug Delivery, 2016, 23, 2827-2837.	5.7	55
38	Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. International Journal of Pharmaceutics, 2021, 599, 120428.	5.2	54
39	Investigation of Nanoemulsion System for Transdermal Delivery of Domperidone: Ex-vivo and in vivo Studies. Current Nanoscience, 2008, 4, 381-390.	1.2	53
40	Design and development of novel bioadhesive niosomal formulation for the transcorneal delivery of anti-infective agent: In-vitro and ex-vivo investigations. Asian Journal of Pharmaceutical Sciences, 2015, 10, 322-330.	9.1	50
41	Design expert assisted nanoformulation design for co-delivery of topotecan and thymoquinone: Optimization, in vitro characterization and stability assessment. Journal of Molecular Liquids, 2017, 242, 382-394.	4.9	49
42	Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: Application to pharmacokinetic studies. Talanta, 2008, 76, 1015-1021.	5.5	46
43	Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer. International Journal of Biological Macromolecules, 2015, 73, 222-235.	7.5	46
44	Lutein, a versatile phyto-nutraceutical: An insight on pharmacology, therapeutic indications, challenges and recent advances in drug delivery. PharmaNutrition, 2017, 5, 64-75.	1.7	46
45	Development and optimization of ketoconazole loaded nano-transfersomal gel for vaginal delivery using Box-Behnken design: InÂvitro , exÂvivo characterization and antimicrobial evaluation. Journal of Drug Delivery Science and Technology, 2017, 39, 95-103.	3.0	45
46	Preparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancer. Journal of Molecular Liquids, 2018, 249, 609-616.	4.9	45
47	Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine: Nanotechnology, Biology, and Medicine, 2009, 5, 55-63.	3.3	43
	Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine,) Tj ETQq0 0 0 rgB	Г /Overlocl	k 10 Tf 50 31
48	absorption studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 261-266.	2.3	42
49	Validated high-performance thin-layer chromatography method for determination of trigonelline in herbal extract and pharmaceutical dosage form. Analytica Chimica Acta, 2006, 577, 46-51.	5.4	41
50	Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. Colloids and Surfaces B: Biointerfaces, 2013, 101, 143-151.	5.0	41
51	A vaginal drug delivery model. Drug Delivery, 2016, 23, 3123-3134.	5.7	40
52	Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an <i>in vitro, ex vivo</i> and <i>in vivo</i> investigations. Drug Delivery, 2016, 23, 500-511.	5.7	39
53	Novel 4-in-1 strategy to combat colon cancer, drug resistance and cancer relapse utilizing functionalized bioinspiring lignin nanoparticle. Medical Hypotheses, 2018, 121, 10-14.	1.5	39
54	Co-Delivery of Eugenol and Dacarbazine by Hyaluronic Acid-Coated Liposomes for Targeted Inhibition of Survivin in Treatment of Resistant Metastatic Melanoma. Pharmaceutics, 2019, 11, 163.	4.5	39

#	Article	IF	CITATIONS
55	Design and Development of Oral Oil-in-Water Nanoemulsion Formulation Bearing Atorvastatin: In Vitro Assessment. Journal of Dispersion Science and Technology, 2010, 31, 690-701.	2.4	38
56	Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: In vitro and in vivo investigations. International Journal of Pharmaceutics, 2014, 477, 454-468.	5.2	36
57	A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. Saudi Pharmaceutical Journal, 2011, 19, 185-191.	2.7	34
58	Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Colloids and Surfaces B: Biointerfaces, 2014, 123, 600-609.	5.0	34
59	Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids and Surfaces B: Biointerfaces, 2014, 123, 610-615.	5.0	33
60	Application of a validated stability-indicating densitometric thin-layer chromatographic method to stress degradation studies on moxifloxacin. Analytica Chimica Acta, 2007, 582, 75-82.	5.4	32
61	Emerging Role of Microemulsions in Cosmetics. Recent Patents on Drug Delivery and Formulation, 2008, 2, 275-289.	2.1	31
62	Chondroitin sulfate-capped super-paramagnetic iron oxide nanoparticles as potential carriers of doxorubicin hydrochloride. Carbohydrate Polymers, 2016, 151, 546-556.	10.2	31
63	Preparation and Characterization of Oil in Water Nano-Reservoir Systems for Improved Oral Delivery of Atorvastatin. Current Nanoscience, 2009, 5, 428-440.	1.2	31
64	Self-Nanoemulsifying Lipid Carrier System for Enhancement of Oral Bioavailability of Etoposide by <l>P</l> -Glycoprotein Modulation: <l>ln Vitro</l> Cell Line and <l>ln Vivo</l> Pharmacokinetic Investigation. Journal of Biomedical Nanotechnology, 2013, 9, 1216-1229.	1.1	29
65	Assessment of Ocular Pharmacokinetics and Safety of Ganciclovir Loaded Nanoformulations. Journal of Biomedical Nanotechnology, 2011, 7, 144-145.	1.1	28
66	Changing Face of Wood Science in Modern Era: Contribution of Nanotechnology. Recent Patents on Nanotechnology, 2018, 12, 13-21.	1.3	28
67	Design and Development of Bioceramic Based Functionalized PLGA Nanoparticles of Risedronate for Bone Targeting: In-vitro Characterization and Pharmacodynamic Evaluation. Pharmaceutical Research, 2015, 32, 3149-3158.	3.5	27
68	Facile functionalization of Teriflunomide-loaded nanoliposomes with Chondroitin sulphate for the treatment of Rheumatoid arthritis. Carbohydrate Polymers, 2020, 250, 116926.	10.2	27
69	Stability indicating high-performance thin-layer chromatographic determination of gatifloxacin as bulk drug and from polymeric nanoparticles. Analytica Chimica Acta, 2006, 576, 253-260.	5.4	26
70	Feasibility of Proniosomes-Based Transdermal Delivery of Frusemide: Formulation Optimization and Pharmacotechnical Evaluation. Pharmaceutical Development and Technology, 2008, 13, 155-163.	2.4	26
71	Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma. International Journal of Biological Macromolecules, 2015, 72, 569-574.	7.5	26
72	Components Screening and Influence of Surfactant and Cosurfactant on Nanoemulsion Formation. Current Nanoscience, 2009, 5, 220-226.	1.2	25

#	Article	IF	CITATIONS
73	Ultra high-pressure liquid chromatographic assay of moxifloxacin in rabbit aqueous humor after topical instillation of moxifloxacin nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 110-113.	2.8	24
74	Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. International Journal of Pharmaceutics, 2016, 501, 18-31.	5.2	24
75	Hyaluronate-functionalized hydroxyapatite nanoparticles laden with methotrexate and teriflunomide for the treatment of rheumatoid arthritis. International Journal of Biological Macromolecules, 2021, 171, 502-513.	7.5	24
76	Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an <i>in-vitro</i> , <i>in-vivo</i> and mechanistic investigation. Journal of Drug Targeting, 2019, 27, 183-192.	4.4	23
77	Nonionic Surfactant Vesicles as a Carrier for Transdermal Delivery of Frusemide. Journal of Dispersion Science and Technology, 2008, 29, 723-730.	2.4	22
78	Lacidipine encapsulated gastroretentive microspheres prepared by chemical denaturation for Pylorospasm. Journal of Microencapsulation, 2009, 26, 385-393.	2.8	22
79	Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis. Journal of Microencapsulation, 2012, 29, 445-454.	2.8	22
80	Rhodamine-loaded, cross-linked, carboxymethyl cellulose sodium-coated super-paramagnetic iron oxide nanoparticles: Development and in vitro localization study for magnetic drug-targeting applications. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2015, 481, 51-62.	4.7	21
81	Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. International Journal of Pharmaceutics, 2016, 506, 253-261.	5.2	21
82	Microemulsion as a Potential Transdermal Carrier for Poorly Water Soluble Antifungal Drug Itraconazole. Journal of Dispersion Science and Technology, 2009, 31, 84-94.	2.4	20
83	Stability Indicating HPTLC Method for Determination of Terbutaline Sulfate in Bulk and from Submicronized Dry Powder Inhalers. Analytical Sciences, 2010, 26, 467-472.	1.6	20
84	Development and Performance Evaluation of Alginate-Capped Amphotericin B Lipid Nanoconstructs Against Visceral Leishmaniasis. Journal of Biomedical Nanotechnology, 2011, 7, 123-124.	1.1	20
85	Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the Treatment of Rheumatoid Arthritis: In Vitro Characterization, Pharmacodynamic and Biochemical Investigations. Pharmaceutical Research, 2018, 35, 201.	3.5	20
86	Dental Therapeutic Systems. Recent Patents on Drug Delivery and Formulation, 2008, 2, 58-67.	2.1	19
87	Buccoadhesive Drug Delivery Systems - Extensive Review on Recent Patents. Recent Patents on Drug Delivery and Formulation, 2008, 2, 177-188.	2.1	18
88	Enhanced transdermal delivery of carvedilol using nanoemulsion as a vehicle. Journal of Experimental Nanoscience, 2010, 5, 390-411.	2.4	18
89	Synergistic anticancer efficacy of Bendamustine Hydrochloride loaded bioactive Hydroxyapatite nanoparticles: In-vitro, ex-vivo and in-vivo evaluation. Colloids and Surfaces B: Biointerfaces, 2016, 146, 852-860.	5.0	18
90	Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations. AAPS PharmSciTech, 2018, 19, 573-589.	3.3	18

#	Article	IF	CITATIONS
91	Polymeric nanoparticles as a platform for permeability enhancement of class III drug amikacin. Colloids and Surfaces B: Biointerfaces, 2018, 169, 206-213.	5.0	17
92	Formulation development and in vitro–in vivo assessment of protransfersomal gel of anti-resorptive drug in osteoporosis treatment. International Journal of Pharmaceutics, 2021, 608, 121060.	5.2	17
93	Development and validation of a stability-indicating method for determination of ropinirole in the bulk drug and in pharmaceutical dosage forms. Acta Chromatographica, 2008, 20, 95-107.	1.3	17
94	A validated stability-indicating LC method for estimation of etoposide in bulk and optimized self-nano emulsifying formulation: Kinetics and stability effects. Saudi Pharmaceutical Journal, 2013, 21, 103-111.	2.7	16
95	Formulation development and optimization of alpha ketoglutarate nanoparticles for cyanide poisoning. Powder Technology, 2011, 211, 1-9.	4.2	14
96	Formulation, Antimicrobial and Toxicity Evaluation of Bioceramic based Ofloxacin Loaded Biodegradable Microspheres for Periodontal Infection. Current Drug Delivery, 2012, 9, 515-526.	1.6	14
97	Quality by design driven development and optimization of teriflunomide loaded nanoliposomes for treatment of rheumatoid arthritis: An in vitro and in vivo assessments. Journal of Drug Delivery Science and Technology, 2019, 51, 383-396.	3.0	14
98	Nanofacilitated synergistic treatment for rheumatoid arthritis: A â€~three-pronged' approach. Medical Hypotheses, 2016, 92, 44-47.	1.5	13
99	In vivo lung deposition and sub-acute inhalation toxicity studies of nano-sized alendronate sodium as an antidote for inhaled toxic substances in Sprague Dawley rats. Environmental Toxicology and Pharmacology, 2013, 36, 636-647.	4.0	12
100	Potential of a novel self nanoemulsifying carrier system to overcome P-glycoprotein mediated efflux of etoposide: InÂvitro and exÂvivo investigations. Journal of Drug Delivery Science and Technology, 2015, 28, 18-27.	3.0	12
101	Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations. Drug Delivery, 2016, 23, 2990-2997.	5.7	12
102	Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases. Current Pharmaceutical Design, 2020, 26, 5488-5502.	1.9	12
103	Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations. Current Drug Delivery, 2019, 16, 902-912.	1.6	12
104	Emerging Role of CD44 Receptor as a Potential Target in Disease Diagnosis: A Patent Review. Recent Patents on Inflammation and Allergy Drug Discovery, 2017, 11, 77-91.	3.6	12
105	Determination of Alendronate Sodium by Box-Behnken Statistical Design. Chromatographia, 2010, 72, 321-326.	1.3	11
106	Nanopotentiated combination cancer therapy: Chemotherapeutic and chemosensitizer (2C approach). Medical Hypotheses, 2015, 84, 580-582.	1.5	11
107	Inverse targeting of diclofenac sodium to reticuloendothelial system-rich organs by sphere-in-oil-in-water (s/o/w) multiple emulsion containing poloxamer 403. Journal of Drug Targeting, 2005, 13, 173-178.	4.4	10
108	Transdermal Therapeutic System of Enalapril Maleate Using Piperidine as Penetration Enhancer. Current Drug Delivery, 2008, 5, 148-152.	1.6	10

#	Article	IF	CITATIONS
109	Study of the Degradation Kinetics of Carvedilol by Use of a Validated Stability-Indicating LC Method. Chromatographia, 2009, 70, 1283-1286.	1.3	10
110	Development and Validation of a Stability-Indicating LC Method for Simultaneous Analysis of Aceclofenac and Paracetamol in Conventional Tablets and in Microsphere Formulations. Chromatographia, 2008, 68, 557-565.	1.3	9
111	An HPTLC Method for the Determination of Minocycline in Human Plasma, Saliva, and Gingival Fluid after Single Step Liquid Extraction. Analytical Sciences, 2009, 25, 57-62.	1.6	9
112	Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice. Molecular and Cellular Endocrinology, 2017, 440, 34-43.	3.2	9
113	Novel Polymer Coupled Lipid Nanoparticle of Paclitaxel with Synergistic Enhanced Efficacy Against Cancer. Journal of Biomedical Nanotechnology, 2011, 7, 125-126.	1.1	8
114	Pulmonary delivery of nanosized alendronate for decorporation of inhaled heavy metals: formulation development, characterization and gamma scintigraphic evaluation. Pharmaceutical Development and Technology, 2014, 19, 623-633.	2.4	8
115	The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 191-199.	1.6	8
116	Liquid chromatographic method for irinotecan estimation: Screening of p-gp modulators. Indian Journal of Pharmaceutical Sciences, 2015, 77, 14.	1.0	8
117	Aqueous Humor Pharmacokinetics of Dorzolamide Loaded PLGAChitosan Nanoparticles by Ultra Performance Liquid Chromatography. Current Pharmaceutical Analysis, 2011, 7, 189-194.	0.6	7
118	Investigation of imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies. International Journal of Pharmaceutics, 2016, 507, 61-71.	5.2	7
119	Combined Raloxifene and Letrozole for Breast Cancer Patients. Archives of Medical Research, 2017, 48, 561-565.	3.3	7
120	Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. Drug Development and Industrial Pharmacy, 2019, 45, 1181-1192.	2.0	7
121	Box-Behnken Design of Experiment Assisted Development and Optimization of Bendamustine HCl loaded Hydroxyapatite Nanoparticles. Current Drug Delivery, 2018, 15, 1230-1244.	1.6	7
122	Aripiprazole Loaded Polymeric Biodegradable Microspheres: Formulation and In Vitro Characterization. Journal of Dispersion Science and Technology, 2009, 30, 1198-1202.	2.4	6
123	Stability-indicating high-performance thin-layer chromatographic method for analysis of terbinafine in pharmaceutical formulations. Acta Chromatographica, 2009, 21, 631-639.	1.3	6
124	Alpha ketoglutarate nanoparticles: A potentially effective treatment for cyanide poisoning. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 126, 221-232.	4.3	6
125	Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors. Medical Hypotheses, 2014, 82, 240-242.	1.5	5
126	Three Ply-Walled Microcapsules for Enhanced Pharmacokinetics of Poorly Absorbed Risedronate Sodium: Novel Stratagem Toward Osteoporosis. Journal of Pharmaceutical Innovation, 2015, 10, 130-139.	2.4	5

#	Article	IF	CITATIONS
127	A STABILITY INDICATING HPTLC METHOD FOR THE ANALYSIS OF IRINOTECAN IN BULK DRUG AND MARKETED INJECTABLES. Journal of Liquid Chromatography and Related Technologies, 2011, 34, 1459-1472.	1.0	4
128	An approach for lacidipine loaded gastroretentive formulation prepared by different methods for gastroparesis in diabetic patients. Saudi Pharmaceutical Journal, 2013, 21, 293-304.	2.7	4
129	Investigative Approaches for Oral Delivery of Anticancer Drugs: A Patent Review. Recent Patents on Drug Delivery and Formulation, 2016, 10, 24-43.	2.1	4
130	Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action. Medical Hypotheses, 2018, 116, 141-146.	1.5	4
131	Development and validation of stability indicating reversedâ€phase liquid chromatographic method for simultaneous quantification of methotrexate and teriflunomide in nanoparticles and marketed formulation. Biomedical Chromatography, 2018, 32, e4372.	1.7	4
132	Particle Engineering in the Perspective of Thermodynamics: A Case Study with Itraconazole. Advanced Science Letters, 2012, 16, 148-158.	0.2	4
133	Nanoemulsion as Carrier for Stability Enhancement of Ramipril. Journal of Dispersion Science and Technology, 2010, 31, 975-979.	2.4	3
134	Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexene diepoxide treated ovotoxic female mice. Fundamental and Clinical Pharmacology, 2016, 30, 429-439.	1.9	3
135	Development and validation of a stability-indicating LC-UV method for rapid analysis of buspirone in pharmaceutical dosage forms. Acta Chromatographica, 2009, 21, 283-297.	1.3	3
136	Development and Validation of UHPLC/ESI-Q-TOF-MS Method for Terbutaline Estimations in Experimental Rodents: Stability Effects and Plasma Pharmacokinetics. Current Pharmaceutical Analysis, 2012, 8, 189-195.	0.6	3
137	Quantification of Tamoxifen Polymeric Nanoparticles in female rodent breast tissue by UPLC/ESI-Q-TOF MS/MS. Journal of Young Pharmacists, 2016, 8, 415-423.	0.2	3
138	Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy. Current Cancer Therapy Reviews, 2009, 5, 89-99.	0.3	2
139	Engineered Site-specific Vesicular Systems for Colonic Delivery: Trends and Implications. Current Pharmaceutical Design, 2020, 26, 5441-5455.	1.9	2
140	A Regulatory Overview of Hip And Knee Joint Replacement Devices. Applied Clinical Research Clinical Trials and Regulatory Affairs, 2019, 6, 212-230.	0.4	1
141	Development of Ethanolic Nano Vesicles of Tenoxicam, Investigation of Transdermal Penetration Efficiency and Histological Safety Comparison with Common Penetration Enhancers. Nanoscience and Nanotechnology Letters, 2013, 5, 600-605.	0.4	1
142	Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2073-2106.	2.5	0
143	Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice. Data in Brief, 2017, 10, 444-448.	1.0	0